Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Divaza for oxidative disorders in cerebral atherosclerosis
NCT03485495Phase 4Completed
- Sponsor
- Materia Medica Holding
- Start
- Apr 2018
- Primary completion
- Apr 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of Divaza in cerebral atherosclerosis, sponsored by Materia Medica Holding. Started Apr 2018; status: completed.
02
Drugs
Divaza
03
Conditions
cerebral atherosclerosis
Beyond the preview
Go deeper on NCT03485495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03485495.